N-115 is under clinical development by EmphyCorp and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how N-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
N-115 overview
N-115 (sodium pyruvate) is under development for treatments of pulmonary diseases like pulmonary fibrosis, interstitial lung disease cystic fibrosis, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disorder, Alzheimer's disease, allergic rhinitis, cancer, asthmatic bronchitis, long covid-19 andcovid-19. It is administered through nasal route. N-115 is a low molecular weight molecule. It acts as a reactive oxygen species (ROS) antagonists in the treatment of pulmonary diseases. It is an antioxidant and an inhaled alpha keto acid drug candidate. Sodium pyruvate reacts directly with oxygen radicals like hydrogen peroxide and peroxynitrite, where it neutralizes them and protecting DNA and other cellular components, such as glutathione, lipids and proteins. Sodium pyruvate regulated the synthesis of nitric oxide (NO) and also protected it from destruction by excess hydrogen peroxide.
See Also:
It was also under treatment for influenza infections.
EmphyCorp overview
EmphyCorp is a pharmaceutical drug discovery company that develops and markets products for the treatment of asthmatic bronchitis and chronic obstructive pulmonary diseases. The company’s products portfolio includes N115 non-steroidal nasal spray, N115 oral spray and OTC N115 nasal spray. It provides products for the treatment of hypoxemia, pulmonary fibrosis, Covid-19, Covid long haulers, flu, asthma, COPD, emphysema, sarcoidosis, cystic fibrosis (CF), chronic bronchitis, interstitial lung disease, viral and bacterial infections, among others. It operates in the US, Canada, Mexico, Japan, the Middle-East, Europe and China. EmphyCorp is headquartered in Flemington, New Jersey, the US.
For a complete picture of N-115’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
